Titan Medical Provides Corporate Update
Titan Medical Inc. (TMD) announced an update regarding its annual filings, indicating a delay in submitting its financial statements for the fiscal year ending December 31, 2022. The company has applied for a management cease trade order (MCTO) to address this late filing, aiming to complete it by May 19, 2023. Titan retains 14 employees focusing on potential asset sales and maintaining compliance. The firm’s strategic review process revealed no interest from potential buyers, leading to cost-cutting measures and layoffs among senior management. The company confirms it is not facing insolvency and is actively preparing its annual filings.
- Titan Medical has the necessary financial resources to remedy the default on Annual Filing Documents.
- The company is actively preparing to file its Annual Filing Documents by the Anticipated Filing Date of May 19, 2023.
- Delay in annual filings could raise regulatory concerns and impact investor confidence.
- The strategic review found no interested parties, indicating potential challenges in monetizing its assets.
TORONTO, ON, April 03, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today provided an update on its annual filings and certain other corporate and operational matters.
On March 22, 2023, the Company announced that it would not be filing its annual financial statements, the related management’s discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2022 (collectively, the “Annual Filing Documents”) within the time period prescribed by National Instrument 51-102 – Continuous Disclosure Obligations and National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and Interim Filings. The Company also announced that it had applied to the Ontario Securities Commission, as its principal regulator, under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults requesting that a management cease trade order (“MCTO”) be imposed in respect of the late filing of its Annual Filing Documents.
The Company has the necessary financial and human resources to remedy the default and file its Annual Filing Documents by May 19, 2023 (the “Anticipated Filing Date”). Titan’s management has prepared a work plan to prepare and finalize the Annual Filing Documents by the Anticipated Filing Date and is actively preparing the filing documents and working to that end. Additionally, the Company plans to engage its existing auditor, BDO Canada LLP, to work with the Company to complete an audit of the Company’s 2022 annual financial statements.
The Company continues to evaluate options for the business including the sale and/or licensing of all or a portion of the Company's assets, including its intellectual property. The Company retains 14 employees who are focused on i) supporting a potential strategic transaction, including a sale and/or licensing of the Company’s assets; ii) maintaining its intellectual property portfolio; iii) continuing to complete deliverables pursuant to certain contractual development and supply obligations; iv) preparing and filings its Annual Filing Documents; and v) continuing corporate administrative and compliance obligations.
The Company confirms that it is not subject to any insolvency proceedings at this time and that there is no other material information concerning its affairs that have not been generally disclosed.
About Titan Medical
Titan Medical Inc. (TSX: TMD), a medical device company headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina, was focused on enhancing robotic assisted surgery (RAS) using innovative technology through a single access point. On November 30, 2022, the Company announced the commencement of a strategic review process that considered a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a portion of the Company’s assets, strategic investment or other significant transaction. On February 8, 2023, the Company announced that none of the parties approached as part of the strategic review process expressed an interest in pursuing a transaction with the Company. As a result, the Company initiated various cost-cutting measures and announced that its board of directors had determined to prioritize the sale of all or a portion of the Company’s assets and subsequently on February 14, 2023, the Company announced that it had laid off a number of senior management personnel.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the Company’s Annual Filings and whether the Company will remedy the default on or before May 19, 2023; whether the MCTO will be granted by the Ontario Securities Commission; the impact of the MCTO on the Company, its shareholders and directors; the Company’s plans to engage BDO Canada LLP; the Company’s ability to complete a strategic transaction, including a sale and/or licensing of some or all of its assets.
These forward-looking statements reflect management’s current beliefs with respect to future events and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, the Company’s ability to retain key personnel; its ability to execute on its business plans and strategies; the sufficiency of its working capital to continue to fund its operations and other factors listed in the “Risk Factors” section of the Company’s Annual Report for the fiscal year ended December 31, 2021 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and the Company has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Contact
Stephen Lemieux
Chief Financial Officer
investors@titanmedicalinc.com
###
FAQ
What is Titan Medical's delay in filing its annual financial statements?
When is Titan Medical's anticipated filing date for its annual documents?
What actions is Titan Medical taking regarding its operations?
Is Titan Medical facing any insolvency issues?
What happened to Titan Medical's strategic review process?
